Accounts Receivable, after Allowance for Credit Loss, Current in USD of Seres Therapeutics, Inc. from Q1 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Seres Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and change rate from Q1 2019 to Q3 2025.
  • Seres Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2025 was $351K.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Seres Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $351K Sep 30, 2025 10-Q 2025-11-05
Q4 2024 $0 Dec 31, 2024 10-Q 2025-11-05
Q3 2021 $1.25M -$2.14M -63.2% Sep 30, 2021 10-Q 2021-11-10
Q2 2021 $1.25M -$1.68M -57.3% Jun 30, 2021 10-Q 2021-08-03
Q1 2021 $2.6M +$520K +25% Mar 31, 2021 10-Q 2021-05-04
Q4 2020 $9.39M +$7.6M +426% Dec 31, 2020 10-K 2022-03-01
Q3 2020 $3.39M +$1.68M +97.6% Sep 30, 2020 10-Q 2020-11-09
Q2 2020 $2.93M +$1.33M +82.6% Jun 30, 2020 10-Q 2020-07-28
Q1 2020 $2.08M -$4.58M -68.7% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 $1.79M Dec 31, 2019 10-K 2021-03-02
Q3 2019 $1.72M Sep 30, 2019 10-Q 2019-11-05
Q2 2019 $1.6M Jun 30, 2019 10-Q 2019-08-06
Q1 2019 $6.67M Mar 31, 2019 10-Q 2019-05-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.